Health care: China's pharmaceutical manufacturing data continued to pick up | recommend 8 shares

Pharmaceutical Network February 6 hearing

Amgen, AstraZeneca, Eli Lilly, Novo Nordisk and Pfizer this week reported that their insulin products, small molecule inhibitor of breast cancer, maintained their growth in 2017. Amgen and Pfizer's etanercept sales totaled $ 7.885 billion , A year-on-year decrease of 11.14%. Pfizer's 13-valent pneumonia vaccine Pei-yer achieved sales revenue of US $ 6,601 million, a decrease of 2.05%; Pregabalin's sales revenue of US $ 5,065 million was listed on the market of 1.99%; notably, breast cancer drug Ibrance (CDK4 / 6 Inhibitor) sales revenue in 2017 soared 46%, breaking the $ 3 billion in the third year of listing.Nowadstream Liraglutide achieved sales revenue of 3.877 billion U.S. dollars, an increase of 38.15% over the same period of last year, aspart insulin sales revenue of 3.35 billion US dollar, up 19.97% over the same period.

2017 year-round medicine Manufacturing data continued to pick up, medicine up turning point, the layout of innovation and leading.

This week the pharmaceutical and biotechnology industry fell 6.0%, Shanghai and Shenzhen 300 fell 2.5%, the pharmaceutical sector underperformed Shanghai and Shenzhen 300 about 3.5% .But from the industry macroeconomic data, the total annual revenue of the pharmaceutical manufacturing industry in 2017 2,181.55 billion yuan , Representing an increase of 12.5% ​​over the same period of last year, representing an increase of 2.8 percentage points as compared with the same period of 2016. The accumulated profit of RMB331.41 billion, an increase of 17.8% as compared with the same period of last year and an increase of 3.9 percentage points as compared with the same period in 2016 continued to show a clear warming trend. , It is recommended to focus attention on the 2017 annual report and the 2018 first quarter results are expected to exceed expectations enterprise We have made statistics on the forecast of the annual report performance of the 189 pharmaceutical listed companies that have been announced at present. Among them, 27 companies have a median growth rate of over 100%, 27 have a 50% -100% median value, 91 have a 0% -50% , There are 44 negative growth enterprises, while 10 companies issue performance bulletin and 1 company announces annual report.It is recommended to layout ahead of schedule the performance growth is determined and the valuation is reasonable or low varieties, it is recommended to pay attention to wisdom fly biology, Tiger Medical , Livzon Group, Hong Hong Pharmaceutical, the establishment of medical treatment, Pien Tze Huang and other companies faster growth.